Please login to the form below

Not currently logged in
Email:
Password:

Horizon Discovery appoints executive director

David Smoller is chief business officer at the genomics firm
david-smoller horizon

UK-based genetic research company Horizon Discovery has named Dr David Smoller as an executive director of the board.

Smoller joined Horizon as chief business officer as part of the form's acquisition of Sage Labs for $48m in September this year.

Of his appointment, he said: “The integration of Sage Labs and Horizon is progressing well and I am delighted to be joining the Horizon board at this exciting time for the company.”

His previous roles include the position of CEO at Sage Labs, chief scientific officer of Sigma-Aldrich and president of its research biotechnology business unit.

He also served as president of ProteoPlex, a seed stage spinout focusing on proteomics, which was acquired by Merck KGaA in 2003, and founded Genomes Systems, acquired by Incyte Genomics in 1996.

Horizon is a UK-based biotech focused on genomics research and the development of personalised medicines. It has partnerships with several major pharma companies, including AstraZeneca.

The company has undergone expansion in recent years with other senior appointments including GSK and Abbott veteran Dr Ian Gilham as chairman and the addition of AstraZeneca's head of oncology R&D Susan Galbraith to Horizon's board.

4th November 2014

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....